AXSM - アクサム・セラピュ―ティクス (Axsome Therapeutics Inc.) アクサム・セラピュ―ティクス

 AXSMのチャート


 AXSMの企業情報

symbol AXSM
会社名 Axsome Therapeutics Inc (アクサム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate AXS-02 (disodium zoledronate tetrahydrate) is an oral targeted non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) and chronic low back pain (CLBP) associated with type I or mixed type I and type II Modic changes (MCs). Its product candidate AXS 05 is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions such as treatment resistant depression (TRD) and agitation in patients with Alzheimer''s disease (AD).   アクサム・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、痛みと中枢神経系障害のための治療法の開発に従事。医薬品候補の「AXS-02」は非オピオイドの経口薬で、慢性的な痛みの治療に使用される。また「AXS-05」はデキストロメトルファンとブプロピオンの一定量を組み合わせた革新的な治療薬である。本社はニューヨーク。   Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
本社所在地 25 Broadway 9th Floor New York NY 10004 USA
代表者氏名 Herriot Tabuteau Herriot Tabuteau
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 212-203-5072
設立年月日 40909
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 25人
url www.axsome.com
nasdaq_url https://www.nasdaq.com/symbol/axsm
adr_tso
EBITDA EBITDA(百万ドル) -27.84864
終値(lastsale) 3.39
時価総額(marketcap) 88997202.18
時価総額 時価総額(百万ドル) 93.50153
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 81.62078
当期純利益 当期純利益(百万ドル) -26.95052
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Axsome Therapeutics Inc revenues was not reported. Net loss decreased 13% to $13.1M. Lower net loss reflects Research and development - Other decrease of 6% to $10.1M (expense) Stock-based Compensation in SGA decrease of 9% to $788K (expense) Stock-based Compensation in R&D decrease of 21% to $221K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.51.

 AXSMのテクニカル分析


 AXSMのニュース

   One of America's richest Black people is hiding in plain sight. His $2.2 billion pharma company could improve life for millions of people with Alzheimer's.  2021/03/29 12:49:56 Business Insider
Summary List Placement In the US, about 6.2 million people have Alzheimer's disease. About 70% experience agitation — extreme emotional distress that can manifest as resisting care, shouting, or becoming physically violent — and 40% have symptoms severe enough to require treatment, Dr. Jeffrey Cummings told Insider. But there isn't a single approved drug to treat agitation in people with Alzheimer's. "This is a major problem," said Cummings, a leading Alzheimer's researcher and a professor at the University of Nevada Las Vegas. "It is one of the principal reasons that Alzheimer's patients are admitted to long-term care because they can't be managed at home." Axsome Therapeutics, a biopharmaceutical firm in New York, could change this. The Food and Drug Administration has designated one of its medications, AXS-05, a breakthrough therapy for Alzheimer's agitation. In December, Axsome started the last trial necessary to apply for commercial approval. The company has estimated that the medication will go to market in 2023.
   Axsome Therapeutics und Veeva Systems kooperieren beim Aufbau der digital-zentrierten Commercialization™-Plattform von Axsome  2020/11/05 09:17:00 Business Wire
NEW YORK und BARCELONA, Spanien--(BUSINESS WIRE)--Axsome Therapeutics, Inc. (NASDAQ: AXSM), ein biopharmazeutisches Unternehmen, das neuartige Therapien für die Behandlung von Erkrankungen des Zentralnervensystems (ZNS) entwickelt, und Veeva Systems (NYSE: VEEV) gaben heute eine strategische Partnerschaft bekannt, um den Aufbau der digitalzentrierten Kommerzialisierungsplattform von Axsome (DCC™) zu erweitern. Veeva ist der führende Anbieter von Cloud-Lösungen für die globale Biowissenschaftsin
   Immunomedics, Scientific Games: 5 Top Gainers for Monday  2020/09/14 20:21:52 The Street
Immunomedics, Scientific Games, Axsome Therapeutics, Seattle Genetics and Vaxart are some of the top gainers for Monday.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool  2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
   Axsome Therapeutics und Veeva Systems kooperieren beim Aufbau der digital-zentrierten Commercialization™-Plattform von Axsome  2020/11/05 09:17:00 Business Wire
NEW YORK und BARCELONA, Spanien--(BUSINESS WIRE)--Axsome Therapeutics, Inc. (NASDAQ: AXSM), ein biopharmazeutisches Unternehmen, das neuartige Therapien für die Behandlung von Erkrankungen des Zentralnervensystems (ZNS) entwickelt, und Veeva Systems (NYSE: VEEV) gaben heute eine strategische Partnerschaft bekannt, um den Aufbau der digitalzentrierten Kommerzialisierungsplattform von Axsome (DCC™) zu erweitern. Veeva ist der führende Anbieter von Cloud-Lösungen für die globale Biowissenschaftsin
   Immunomedics, Scientific Games: 5 Top Gainers for Monday  2020/09/14 20:21:52 The Street
Immunomedics, Scientific Games, Axsome Therapeutics, Seattle Genetics and Vaxart are some of the top gainers for Monday.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool  2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
   Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
   Axsome Therapeutics und Veeva Systems kooperieren beim Aufbau der digital-zentrierten Commercialization™-Plattform von Axsome  2020/11/05 09:17:00 Business Wire
NEW YORK und BARCELONA, Spanien--(BUSINESS WIRE)--Axsome Therapeutics, Inc. (NASDAQ: AXSM), ein biopharmazeutisches Unternehmen, das neuartige Therapien für die Behandlung von Erkrankungen des Zentralnervensystems (ZNS) entwickelt, und Veeva Systems (NYSE: VEEV) gaben heute eine strategische Partnerschaft bekannt, um den Aufbau der digitalzentrierten Kommerzialisierungsplattform von Axsome (DCC™) zu erweitern. Veeva ist der führende Anbieter von Cloud-Lösungen für die globale Biowissenschaftsin
   Immunomedics, Scientific Games: 5 Top Gainers for Monday  2020/09/14 20:21:52 The Street
Immunomedics, Scientific Games, Axsome Therapeutics, Seattle Genetics and Vaxart are some of the top gainers for Monday.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool  2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
   Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アクサム・セラピュ―ティクス AXSM Axsome Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)